The short answer
Confirm the valerian species and azelastine route first. If the root is Valeriana officinalis, additive drowsiness is a concern with nasal spray; neither the generic root name nor evidence for nasal spray establishes the same risk with eye drops.
What this answer covers
Generic root/rhizome name does not establish Valeriana officinalis. Nasal and ophthalmic medication routes adjudicated separately.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- azelastine
The medicine can affect alertness
Nasal spray may cause somnolence; avoid concurrent CNS depressants because alertness can decrease further. These medication warnings do not supply a supplement-specific adverse-event rate.
What the supplement evidence shows
Federal valerian guidance concerns Valeriana officinalis and advises caution with sedatives. The generic root name does not confirm that species or a particular extract, so this warning requires product confirmation.
The eye-drop formulation is different
The ophthalmic label reports plasma concentrations generally 0.02–0.25 ng/mL after 56 days of treatment. These low measured levels are distinct from the nasal exposure and do not establish an identical systemic interaction. No exact eye-drop combination study was identified.
Apply the advice to the correct route
Tell the pharmacist whether you use nasal spray or eye drops. Nasal labeling directs avoiding other CNS depressants; review the exact supplement before co-use. No protective timing gap was established, and you should not drive while impaired.
Evidence and practical considerations
Side effects & toxicity
Unconfirmed generic valerian identity prevents validation of the original claim with V.officinalis evidence; separate confirmed-species precaution retained.
- Exact scope
- Generic root/rhizome name does not establish Valeriana officinalis. Nasal and ophthalmic medication routes adjudicated separately. with Azelastine hydrochloride nasal spray; ophthalmic drops considered separately.
- Medication form and route
- intranasal medication; ophthalmic medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Nasal spray may cause somnolence; avoid concurrent CNS depressants because alertness can decrease further.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Ophthalmic0.05% azelastine hydrochloride: measured plasma concentrations generally 0.02–0.25 ng/mL after 56 days of eye-drop treatment. Not the nasal CNS-depressant avoidance instruction.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
Same active ingredient, different formulation or combination. Product-specific results cannot be transferred as identical exposure.
Source 3: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sedation is possible but not proven; guidance advises avoiding use with sedatives. The material discussed is Valeriana officinalis.
How this applies: Interpreted for azelastine only within the stated exact preparation and endpoint limits.
No exact azelastine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Research assessment: · Open full citations ↗
Side effects & toxicity
If confirmed as Valeriana officinalis, additive drowsiness with azelastine nasal spray is a conditional concern; no equivalent ophthalmic interaction established.
- Exact scope
- Confirmed Valeriana officinalis root product. with Azelastine hydrochloride nasal spray; ophthalmic drops considered separately.
- Medication form and route
- intranasal medication; oral supplement
What remains uncertain
- No exact-pair incidence or universally protective timing interval.
Factors that may matter: Preparation; Dose; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Nasal spray may cause somnolence; avoid concurrent CNS depressants because alertness can decrease further.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed azelastine
Ophthalmic0.05% azelastine hydrochloride: measured plasma concentrations generally 0.02–0.25 ng/mL after 56 days of eye-drop treatment. Not the nasal CNS-depressant avoidance instruction.
How this applies: Exact azelastine RxCUI 18603 IN, with stated salt/formulation/route bridge.
Same active ingredient, different formulation or combination. Product-specific results cannot be transferred as identical exposure.
Source 3: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sedation is possible but not proven; guidance advises avoiding use with sedatives. The material discussed is Valeriana officinalis.
How this applies: Interpreted for azelastine only within the stated exact preparation and endpoint limits.
No exact azelastine combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact azelastine article with formulation-specific evidence and uncertainty. |
Article revision: 7d7b8197d33aabab
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.